{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.9","upperLimit":"49.4","value":"28.1"},{"groupId":"OG001","lowerLimit":"11.6","upperLimit":"42.7","value":"28.1"},{"groupId":"OG002","lowerLimit":"16.3","upperLimit":"54.7","value":"28.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"103"}],"units":"Participants"}],"description":"Median topotecan systemic clearance for courses 1 and 2.","dispersionType":"Full Range","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"},{"description":"Patients that either failed during Induction therapy or refused randomization","id":"OG002","title":"Not Assigned"}],"paramType":"MEDIAN","populationDescription":"Eligible patients evaluated for topotecan systemic clearance.","reportingStatus":"POSTED","timeFrame":"Day 1 of courses 1-2","title":"Topotecan Systemic Clearance","type":"SECONDARY","unitOfMeasure":"L/h/m2"}